Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | THPO | P40225 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13338131 | 0.89 | EGFR (0.54) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL10473426 | 0.89 | EGFR (0.54) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL11693160 | 0.87 | ALDH1A1 (0.51) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL11411350 | 0.87 | EGFR (0.57) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A | |
| Acetic Acid SCHEMBL20565475 | 0.87 | EGFR (0.66) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL479209 | 0.86 | TSHR (0.55) | EGFRERBB2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1438703 | 0.85 | EGFR (0.55) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL11690263 | 0.84 | TSHR (0.59) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL11441597 | 0.84 | USP2 (0.46) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL10454442 | 0.83 | ALDH1A1 (0.51) | EGFRERBB2ALDH1A1SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4447934-B1 | CARRIER AS A MULTIFUNCTIONAL SYSTEM | LIFESOME THERAPEUTICS SL (ES) | 2025-08-06 | — | — | EP | claimed |
| EP-4074735-B1 | CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS | BIOATLA INC (US) | 2025-05-21 | — | — | EP | claimed |
| CN-110423212-B | Hydroxy indole carboxylic acid-based inhibitors of SHP2 | 美国印第安纳大学研究和技术公司 | 2023-05-09 | — | — | CN | claimed |
| EP-3210627-B1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO LTD (CN) | 2022-12-21 | — | — | EP | claimed |
| EP-3186284-B1 | CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS | BIOATLA INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-20220073910-A1 | A Cross-Linking Approach to Map Small Molecule-RNA Binding Sites in Cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | claimed |
| WO-2020167811-A1 | A CROSS-LINKING APPROACH TO MAP SMALL MOLECULE-RNA BINDING SITES IN CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-20 | — | — | WO | claimed |
| CN-109438321-A | A kind of tryptophan derivative and its preparation method and application | 南京友怡医药科技有限公司 | 2019-03-08 | — | — | CN | claimed |
| US-20180044362-A1 | PLATINUM PRODRUGS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2018-02-15 | — | — | US | claimed |
| WO-2016144889-A1 | PLATINUM PRODRUGS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-09-15 | — | — | WO | claimed |
| US-20030216871-A1 | Calculating a characteristic property of a molecule by correlation analysis | ICE ENERGY, INC. | 2003-11-20 | — | — | US | claimed |
| US-20030129617-A1 | Calculating a biological characteristic property of a molecule by correlation analysis | PROLOG CAPITAL A, L.P. | 2003-07-10 | — | — | US | claimed |
| WO-2003012439-A2 | METHOD FOR CALCULATING A BIOLOGICAL CHARACTERISTIC PROPERTY OF A MOLECULE BY CORRELATION ANALYSIS | APT THERAPEUTICS, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| WO-2003012676-A2 | METHOD FOR CALCULATING A CHARACTERISTIC PROPERTY OF A MOLECULE BY CORRELATION ANALYSIS | APT THERAPEUTICS, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| EP-0520226-B2 | Halogen scavenger composition | ST CHEMICAL CO LTD (JP) | 2000-10-11 | — | — | EP | claimed |
| US-5968933-A | ANTITUMOR AGENTS AND BINDING DNA FOR MUTAGENESIS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1999-10-19 | — | — | US | claimed |
| EP-0777656-A4 | NOVEL DNA-TARGETED ALKYLATING AGENTS | CANCER SOC AUCKLAND DIV NZ INC (NZ) | 1998-04-15 | — | — | EP | claimed |
| EP-0777656-A1 | NOVEL DNA-TARGETED ALKYLATING AGENTS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND (INCORPORATED) (NZ) | 1997-06-11 | — | — | EP | claimed |
| WO-1996006831-A1 | NOVEL DNA-TARGETED ALKYLATING AGENTS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1996-03-07 | — | — | WO | claimed |
| US-4439380-A | Photopolymerizable composition, especially for dental purposes | ETABLISSEMENT DENTAIRE IVOCLAR (LI) | 1984-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044362-A1 | PLATINUM PRODRUGS AND METHODS OF MAKING AND USING THEREOF | MGMT, DPYD, OGG1 | EGFR 1196/4885ERBB2 1874/4885ALDH1A1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.